VivoSeq
Oncology

Cancers

2

Pipeline Programs↗

12

Active Trials↗

10

Companies Involved↗

Cancers is an early-stage landscape with 2 programs across 10 companies. The most active players are Jazz Pharmaceuticals, ALX Oncology Inc., Mersana Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

61/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

PreclinicalA

ALX Oncology Inc.

1 program

PreclinicalM

Mersana Therapeutics

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalR

Recursion Pharmaceuticals Inc.

0 programs

PreclinicalG

GamaMabs Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical2

Zanidatamab

Jazz Pharmaceuticals

Evorpacept

ALX Oncology Inc.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Monoclonal antibody150%
Protein / enzyme150%

Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed14 · 38%
Recruiting8 · 22%
Terminated7 · 19%
Active, not recruiting4 · 11%
No longer available2 · 5%
Withdrawn1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

37 trials

F-Tryptophan PET/CT in Human Cancers
Recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT05556473·24 enrolled
Metabolomics of Cancers of the Upper Aerodigestive Tract
Recruiting·CCentre Antoine Lacassagne·N/A·NCT07377084·250 enrolled
Precision Cancer Therapy in Rare Cancers
Recruiting·OOslo University Hospital·Phase 2·NCT06119789·96 enrolled
PREventing Second Cancers With DOSTARlimab
Recruiting·CCentre Leon Berard·Phase 2·NCT05855811·400 enrolled
HP Pyruvate MRI in Cancers
Recruiting·UUniversity of Maryland, Baltimore·Phase 1/2·NCT05697406·25 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT02830724·124 enrolled
Acquisition of Data, Blood, and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Recruiting·National Cancer Institute (NCI)·N/A·NCT01313442·550 enrolled
Multi-center Phase I/II Clinical Trial of 4SCAR-CD44v6 T Cells for Treating Cancer
Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT04427449·100 enrolled
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02675829·131 enrolled
PREVENT HPV -Related Cancers Trial
Active, not recruiting·UUniversity of Utah·N/A·NCT07217145·1,455 enrolled
huCART19-IL18 in CD19+ Cancers
Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT04684563·72 enrolled
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Active, not recruiting·MMersana Therapeutics·Phase 1/2·NCT03319628·523 enrolled
CART-meso in Mesothelin Expressing Cancers
Completed·UUniversity of Pennsylvania·Phase 1·NCT02159716·19 enrolled
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
Completed·—·Phase 2·NCT03926936·17 enrolled
Selumetinib in Cancers With BRAF Mutations
Completed·National Cancer Institute (NCI)·Phase 2·NCT00888134·28 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)